Biotechnology
Compare Stocks
4 / 10Stock Comparison
FTRE vs MEDP vs IQV vs ICLR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Medical - Diagnostics & Research
FTRE vs MEDP vs IQV vs ICLR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $1.47B | $12.24B | $30.32B | $9.54B |
| Revenue (TTM) | $2.71B | $2.68B | $16.63B | $8.10B |
| Net Income (TTM) | $-447M | $460M | $1.39B | $599M |
| Gross Margin | 12.1% | 29.1% | 26.1% | 26.9% |
| Operating Margin | -1.1% | 21.0% | 13.9% | 12.2% |
| Forward P/E | 23.0x | 25.2x | 14.1x | 10.5x |
| Total Debt | $68M | $250M | $16.17B | $3.60B |
| Cash & Equiv. | $175M | $497M | $1.98B | $539M |
FTRE vs MEDP vs IQV vs ICLR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 23 | May 26 | Return |
|---|---|---|---|
| Fortrea Holdings In… (FTRE) | 100 | 45.8 | -54.2% |
| Medpace Holdings, I… (MEDP) | 100 | 178.5 | +78.5% |
| IQVIA Holdings Inc. (IQV) | 100 | 79.5 | -20.5% |
| ICON Public Limited… (ICLR) | 100 | 50.0 | -50.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FTRE vs MEDP vs IQV vs ICLR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FTRE is the #2 pick in this set and the best alternative if momentum is your priority.
- +176.6% vs ICLR's -10.0%
MEDP carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.26
- Rev growth 20.0%, EPS growth 21.0%, 3Y rev CAGR 20.1%
- 14.4% 10Y total return vs IQV's 166.5%
- Lower volatility, beta 1.26, Low D/E 54.6%, current ratio 0.74x
IQV is the clearest fit if your priority is valuation efficiency.
- PEG 0.35 vs ICLR's 1.50
ICLR is the clearest fit if your priority is defensive.
- Beta 1.60, current ratio 1.26x
- Lower P/E (10.5x vs 25.2x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.0% revenue growth vs FTRE's 1.0% | |
| Value | Lower P/E (10.5x vs 25.2x) | |
| Quality / Margins | 17.2% margin vs FTRE's -16.5% | |
| Stability / Safety | Beta 1.26 vs FTRE's 2.35 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +176.6% vs ICLR's -10.0% | |
| Efficiency (ROA) | 24.8% ROA vs FTRE's -16.3%, ROIC 154.9% vs -1.6% |
FTRE vs MEDP vs IQV vs ICLR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FTRE vs MEDP vs IQV vs ICLR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MEDP leads in 3 of 6 categories
ICLR leads 1 • FTRE leads 0 • IQV leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
MEDP leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IQV is the larger business by revenue, generating $16.6B annually — 6.2x MEDP's $2.7B. MEDP is the more profitable business, keeping 17.2% of every revenue dollar as net income compared to FTRE's -16.5%. On growth, MEDP holds the edge at +26.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $2.7B | $2.7B | $16.6B | $8.1B |
| EBITDAEarnings before interest/tax | $48M | $577M | $3.5B | $1.4B |
| Net IncomeAfter-tax profit | -$447M | $460M | $1.4B | $599M |
| Free Cash FlowCash after capex | $215M | $745M | $2.7B | $996M |
| Gross MarginGross profit ÷ Revenue | +12.1% | +29.1% | +26.1% | +26.9% |
| Operating MarginEBIT ÷ Revenue | -1.1% | +21.0% | +13.9% | +12.2% |
| Net MarginNet income ÷ Revenue | -16.5% | +17.2% | +8.3% | +7.4% |
| FCF MarginFCF ÷ Revenue | +8.0% | +27.8% | +16.1% | +12.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.3% | +26.5% | +8.4% | +0.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +95.9% | +16.6% | +15.0% | -98.7% |
Valuation Metrics
ICLR leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 13.1x trailing earnings, ICLR trades at a 53% valuation discount to MEDP's 28.1x P/E. Adjusting for growth (PEG ratio), IQV offers better value at 0.56x vs ICLR's 1.87x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1.5B | $12.2B | $30.3B | $9.5B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $12.0B | $44.5B | $12.6B |
| Trailing P/EPrice ÷ TTM EPS | -1.44x | 28.06x | 22.79x | 13.12x |
| Forward P/EPrice ÷ next-FY EPS est. | 23.00x | 25.24x | 14.06x | 10.53x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.88x | 0.56x | 1.87x |
| EV / EBITDAEnterprise value multiple | 28.82x | 21.31x | 12.97x | 7.95x |
| Price / SalesMarket cap ÷ Revenue | 0.54x | 4.84x | 1.86x | 1.15x |
| Price / BookPrice ÷ Book value/share | 2.52x | 27.57x | 4.67x | 1.09x |
| Price / FCFMarket cap ÷ FCF | 16.68x | 17.96x | 14.78x | 8.53x |
Profitability & Efficiency
MEDP leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
MEDP delivers a 120.9% return on equity — every $100 of shareholder capital generates $121 in annual profit, vs $-79 for FTRE. FTRE carries lower financial leverage with a 0.12x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), ICLR scores 7/9 vs IQV's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -79.1% | +120.9% | +22.1% | +6.3% |
| ROA (TTM)Return on assets | -16.3% | +24.8% | +4.7% | +3.6% |
| ROICReturn on invested capital | -1.6% | +154.9% | +8.7% | +6.5% |
| ROCEReturn on capital employed | -1.4% | +65.7% | +11.0% | +7.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.12x | 0.55x | 2.44x | 0.38x |
| Net DebtTotal debt minus cash | -$107M | -$247M | $14.2B | $3.1B |
| Cash & Equiv.Liquid assets | $175M | $497M | $2.0B | $539M |
| Total DebtShort + long-term debt | $68M | $250M | $16.2B | $3.6B |
| Interest CoverageEBIT ÷ Interest expense | -7.33x | — | 3.10x | 3.96x |
Total Returns (Dividends Reinvested)
MEDP leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MEDP five years ago would be worth $25,938 today (with dividends reinvested), compared to $4,866 for FTRE. Over the past 12 months, FTRE leads with a +176.6% total return vs ICLR's -10.0%. The 3-year compound annual growth rate (CAGR) favors MEDP at 27.0% vs FTRE's -21.3% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.4% | -24.9% | -20.7% | -33.7% |
| 1-Year ReturnPast 12 months | +176.6% | +42.9% | +16.5% | -10.0% |
| 3-Year ReturnCumulative with dividends | -51.3% | +104.6% | -5.9% | -34.1% |
| 5-Year ReturnCumulative with dividends | -51.3% | +159.4% | -23.8% | -45.4% |
| 10-Year ReturnCumulative with dividends | -51.3% | +1442.7% | +166.5% | +91.0% |
| CAGR (3Y)Annualised 3-year return | -21.3% | +27.0% | -2.0% | -13.0% |
Risk & Volatility
Evenly matched — FTRE and MEDP each lead in 1 of 2 comparable metrics.
Risk & Volatility
MEDP is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than FTRE's 2.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FTRE currently trades 83.4% from its 52-week high vs ICLR's 59.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.35x | 1.26x | 1.33x | 1.60x |
| 52-Week HighHighest price in past year | $18.67 | $628.92 | $247.05 | $211.00 |
| 52-Week LowLowest price in past year | $3.97 | $284.48 | $134.65 | $66.57 |
| % of 52W HighCurrent price vs 52-week peak | +83.4% | +68.2% | +72.3% | +59.2% |
| RSI (14)Momentum oscillator 0–100 | 82.8 | 40.6 | 58.5 | 62.1 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 371K | 1.6M | 1.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: FTRE as "Hold", MEDP as "Hold", IQV as "Buy", ICLR as "Buy". Consensus price targets imply 26.3% upside for IQV (target: $226) vs 16.4% for MEDP (target: $499).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $18.83 | $498.86 | $225.63 | $149.63 |
| # AnalystsCovering analysts | 12 | 19 | 44 | 30 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 2 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +7.5% | +4.1% | +5.2% |
MEDP leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ICLR leads in 1 (Valuation Metrics). 1 tied.
FTRE vs MEDP vs IQV vs ICLR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FTRE or MEDP or IQV or ICLR a better buy right now?
For growth investors, Medpace Holdings, Inc.
(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus 1. 0% for Fortrea Holdings Inc. (FTRE). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FTRE or MEDP or IQV or ICLR?
On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.
1x versus Medpace Holdings, Inc. at 28. 1x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus ICON Public Limited Company's 1. 50x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — FTRE or MEDP or IQV or ICLR?
Over the past 5 years, Medpace Holdings, Inc.
(MEDP) delivered a total return of +159. 4%, compared to -51. 3% for Fortrea Holdings Inc. (FTRE). Over 10 years, the gap is even starker: MEDP returned +1443% versus FTRE's -51. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FTRE or MEDP or IQV or ICLR?
By beta (market sensitivity over 5 years), Medpace Holdings, Inc.
(MEDP) is the lower-risk stock at 1. 26β versus Fortrea Holdings Inc. 's 2. 35β — meaning FTRE is approximately 87% more volatile than MEDP relative to the S&P 500. On balance sheet safety, Fortrea Holdings Inc. (FTRE) carries a lower debt/equity ratio of 12% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — FTRE or MEDP or IQV or ICLR?
By revenue growth (latest reported year), Medpace Holdings, Inc.
(MEDP) is pulling ahead at 20. 0% versus 1. 0% for Fortrea Holdings Inc. (FTRE). On earnings-per-share growth, the picture is similar: ICON Public Limited Company grew EPS 28. 8% year-over-year, compared to -194. 6% for Fortrea Holdings Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FTRE or MEDP or IQV or ICLR?
Medpace Holdings, Inc.
(MEDP) is the more profitable company, earning 17. 8% net margin versus -36. 2% for Fortrea Holdings Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus -1. 1% for FTRE. At the gross margin level — before operating expenses — MEDP leads at 30. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FTRE or MEDP or IQV or ICLR more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus ICON Public Limited Company's 1. 50x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10. 5x forward P/E versus 25. 2x for Medpace Holdings, Inc. — 14. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 26. 3% to $225. 63.
08Which pays a better dividend — FTRE or MEDP or IQV or ICLR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is FTRE or MEDP or IQV or ICLR better for a retirement portfolio?
For long-horizon retirement investors, Medpace Holdings, Inc.
(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). Fortrea Holdings Inc. (FTRE) carries a higher beta of 2. 35 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1443%, FTRE: -51. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FTRE and MEDP and IQV and ICLR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FTRE is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock; IQV is a mid-cap quality compounder stock; ICLR is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.